Tamoxifen for Breast Cancer Risk

Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Rutgers, The State University of New Jersey
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to learn whether a shorter-duration, low-dose tamoxifen regimen can reduce the risk of developing breast cancer or breast cancer recurrence in post-menopausal women who are at increased risk for breast cancer.

Who Is on the Research Team?

MG

Mridula George, MD

Principal Investigator

Rutgers Cancer Institute

Are You a Good Fit for This Trial?

This trial is for post-menopausal women who have a higher risk of developing breast cancer or having it come back. Specific inclusion and exclusion criteria are not listed, but participants must be at increased risk for breast cancer.

Inclusion Criteria

I am post-menopausal with a breast lesion 3cm or smaller, diagnosed as DCIS, LCIS, ADH, or ALH.
I do not have high-risk breast cancer genes or a strong family history of breast cancer.
I received radiation for DCIS if my doctor recommended it.
See 10 more

Exclusion Criteria

I have had both breasts removed to lower my cancer risk.
Patients who are known to be pregnant
Life expectancy of less than 1 year per treating physician
See 5 more

What Are the Treatments Tested in This Trial?

Interventions

  • Tamoxifen

Trial Overview

The study is testing if taking tamoxifen (Nolvadex) at a lower dose and for a shorter time can help prevent breast cancer or its return in high-risk women. Different durations of treatment will be compared.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Low dose TamoxifenExperimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Rutgers, The State University of New Jersey

Lead Sponsor

Trials
471
Recruited
81,700+